Evidence map›Paper›PMID 28947968›Full record

ArticleOncotarget2017

Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue.

Emelie Rådestad, Lars Egevad, Carl Jorns, Jonas Mattsson, Berit Sundberg, Silvia Nava, Bo-Göran Ericzon, Lars Henningsohn, Victor Levitsky, Michael Uhlin

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Emelie RådestadDepartment of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Lars EgevadDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Carl JornsDepartment of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Jonas MattssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Berit SundbergDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Silvia NavaDepartment of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Bo-Göran EriczonDepartment of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Lars HenningsohnDepartment of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Victor LevitskyMolecular Partners AG, Schlieren-Zurich, Switzerland.
Michael UhlinDepartment of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SEKarolinska University Hospital · SEMolecular Partners (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint blockade has shown promising results in numerous cancer types. However, in prostate cancer (PC), absent or limited responses have been reported. To investigate further, we compared the phenotype of infiltrating T-cells isolated from prostate tissue from patients with PC (

Indexed as

benign prostatic hyperplasiacheckpoint blockadePD-1prostate cancerprostate-infiltrating lymphocytes

Identifiers

PMID28947968
PMCPMC5601136
OpenAlexW2736429521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.